First Time Loading...

Eton Pharmaceuticals Inc
NASDAQ:ETON

Watchlist Manager
Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc
NASDAQ:ETON
Watchlist
Price: 3.06 USD -2.55%
Updated: Apr 19, 2024

Intrinsic Value

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. [ Read More ]

The intrinsic value of one ETON stock under the Base Case scenario is 5.36 USD. Compared to the current market price of 3.06 USD, Eton Pharmaceuticals Inc is Undervalued by 43%.

Key Points:
ETON Intrinsic Value
Base Case
5.36 USD
Undervaluation 43%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eton Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ETON stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Eton Pharmaceuticals Inc

Provide an overview of the primary business activities
of Eton Pharmaceuticals Inc.

What unique competitive advantages
does Eton Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Eton Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Eton Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Eton Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Eton Pharmaceuticals Inc.

Provide P/S
for Eton Pharmaceuticals Inc.

Provide P/E
for Eton Pharmaceuticals Inc.

Provide P/OCF
for Eton Pharmaceuticals Inc.

Provide P/FCFE
for Eton Pharmaceuticals Inc.

Provide P/B
for Eton Pharmaceuticals Inc.

Provide EV/S
for Eton Pharmaceuticals Inc.

Provide EV/GP
for Eton Pharmaceuticals Inc.

Provide EV/EBITDA
for Eton Pharmaceuticals Inc.

Provide EV/EBIT
for Eton Pharmaceuticals Inc.

Provide EV/OCF
for Eton Pharmaceuticals Inc.

Provide EV/FCFF
for Eton Pharmaceuticals Inc.

Provide EV/IC
for Eton Pharmaceuticals Inc.

Show me price targets
for Eton Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Eton Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Eton Pharmaceuticals Inc?

What are the Net Income projections
for Eton Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Eton Pharmaceuticals Inc?

What are the EPS projections
for Eton Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Eton Pharmaceuticals Inc?

What are the EBIT projections
for Eton Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Eton Pharmaceuticals Inc?

Compare the revenue forecasts
for Eton Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Eton Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Eton Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Eton Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Eton Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Eton Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Eton Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Eton Pharmaceuticals Inc.

Provide ROE
for Eton Pharmaceuticals Inc.

Provide ROA
for Eton Pharmaceuticals Inc.

Provide ROIC
for Eton Pharmaceuticals Inc.

Provide ROCE
for Eton Pharmaceuticals Inc.

Provide Gross Margin
for Eton Pharmaceuticals Inc.

Provide Operating Margin
for Eton Pharmaceuticals Inc.

Provide Net Margin
for Eton Pharmaceuticals Inc.

Provide FCF Margin
for Eton Pharmaceuticals Inc.

Show all solvency ratios
for Eton Pharmaceuticals Inc.

Provide D/E Ratio
for Eton Pharmaceuticals Inc.

Provide D/A Ratio
for Eton Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Eton Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Eton Pharmaceuticals Inc.

Provide Quick Ratio
for Eton Pharmaceuticals Inc.

Provide Current Ratio
for Eton Pharmaceuticals Inc.

Provide Cash Ratio
for Eton Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Eton Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Eton Pharmaceuticals Inc?

What is the current Free Cash Flow
of Eton Pharmaceuticals Inc?

Financials

Balance Sheet Decomposition
Eton Pharmaceuticals Inc

Current Assets 26.8m
Cash & Short-Term Investments 21.4m
Receivables 3.4m
Other Current Assets 2m
Non-Current Assets 4.9m
PP&E 150k
Intangibles 4.7m
Other Non-Current Assets 12k
Current Liabilities 16.2m
Accounts Payable 1.8m
Accrued Liabilities 9m
Other Current Liabilities 5.4m
Non-Current Liabilities 22k
Other Non-Current Liabilities 22k
Efficiency

Earnings Waterfall
Eton Pharmaceuticals Inc

Revenue
31.6m USD
Cost of Revenue
-10.6m USD
Gross Profit
21.1m USD
Operating Expenses
-22.3m USD
Operating Income
-1.2m USD
Other Expenses
256k USD
Net Income
-936k USD

Free Cash Flow Analysis
Eton Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ETON Profitability Score
Profitability Due Diligence

Eton Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
Exceptional 1-Year Revenue Growth
32/100
Profitability
Score

Eton Pharmaceuticals Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

ETON Solvency Score
Solvency Due Diligence

Eton Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
40/100
Solvency
Score

Eton Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ETON Price Targets Summary
Eton Pharmaceuticals Inc

Wall Street analysts forecast ETON stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ETON is 10.2 USD with a low forecast of 10.1 USD and a high forecast of 10.5 USD.

Lowest
Price Target
10.1 USD
230% Upside
Average
Price Target
10.2 USD
233% Upside
Highest
Price Target
10.5 USD
243% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ETON Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ETON Price
Eton Pharmaceuticals Inc

1M 1M
-14%
6M 6M
-19%
1Y 1Y
-16%
3Y 3Y
-61%
5Y 5Y
-60%
10Y 10Y
-51%
Annual Price Range
3.06
52w Low
2.55
52w High
5.63
Price Metrics
Average Annual Return -18.36%
Standard Deviation of Annual Returns 25.68%
Max Drawdown -80%
Shares Statistics
Market Capitalization 78.6m USD
Shares Outstanding 25 690 000
Percentage of Shares Shorted 0.91%

ETON Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

78.6m USD

Dividend Yield

0%

Description

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

Contact

ILLINOIS
Deer Park
21925 W Field Pkwy Ste 235
+18477877361.0
https://etonpharma.com/

IPO

2018-11-09

Employees

17

Officers

President, CEO & Director
Mr. Sean E. Brynjelsen
CFO, Treasurer & Secretary
Mr. James R. Gruber CPA
Chief Business Officer
Mr. David C. Krempa
Senior Vice President of Regulatory Affairs
Ms. Ingrid Hoos
Executive VP of Commercial Operations
Mr. Kevin Guthrie

See Also

Discover More
What is the Intrinsic Value of one ETON stock?

The intrinsic value of one ETON stock under the Base Case scenario is 5.36 USD.

Is ETON stock undervalued or overvalued?

Compared to the current market price of 3.06 USD, Eton Pharmaceuticals Inc is Undervalued by 43%.